382 related articles for article (PubMed ID: 35668531)
1. The current state of molecular profiling in gastrointestinal malignancies.
Mukherji R; Yin C; Hameed R; Alqahtani AZ; Kulasekaran M; He AR; Weinberg BA; Marshall JL; Hartley ML; Noel MS
Biol Direct; 2022 Jun; 17(1):15. PubMed ID: 35668531
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Utility of Circulating Tumor DNA Analysis for Precision Medicine in Patients with Advanced Gastrointestinal Cancer].
Nakamura Y
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1191-1196. PubMed ID: 34657046
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for personalized medicine in GI cancers.
Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Application of Circulating Tumor Cells and DNAs as Prognostic and Predictive Biomarkers in Gastrointestinal Cancer.
Memarpour S; Khalili-Tanha G; Ghannad AA; Razavi MS; Joudi M; Joodi M; Ferns GA; Hassanian SM; Khazaei M; Avan A
Curr Cancer Drug Targets; 2021; 21(8):676-688. PubMed ID: 33719973
[TBL] [Abstract][Full Text] [Related]
5. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
6. Cell-free RNA for the liquid biopsy of gastrointestinal cancer.
Xing S; Zhu Y; You Y; Wang S; Wang H; Ning M; Jin H; Liu Z; Zhang X; Yu C; Lu ZJ
Wiley Interdiscip Rev RNA; 2023; 14(5):e1791. PubMed ID: 37086051
[TBL] [Abstract][Full Text] [Related]
7. The potential of liquid biopsies in gastrointestinal cancer.
Wu C; Zhang J; Li H; Xu W; Zhang X
Clin Biochem; 2020 Oct; 84():1-12. PubMed ID: 32540214
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
9. Molecular Profiling of Liquid Biopsies for Precision Oncology.
Gonzalez-Kozlova EE
Adv Exp Med Biol; 2022; 1361():235-247. PubMed ID: 35230692
[TBL] [Abstract][Full Text] [Related]
10. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
11. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
12. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.
Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M
Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032
[TBL] [Abstract][Full Text] [Related]
13. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
14. Development of circulating tumour DNA analysis for gastrointestinal cancers.
Nakamura Y; Shitara K
ESMO Open; 2020 Jan; 5(Suppl 1):e000600. PubMed ID: 32830648
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling in oncology clinical practice.
Rodríguez N; Viñal D; Rodríguez-Cobos J; De Castro J; Domínguez G
Clin Transl Oncol; 2020 Sep; 22(9):1430-1439. PubMed ID: 31981077
[TBL] [Abstract][Full Text] [Related]
16. A clinician's handbook for using ctDNA throughout the patient journey.
Hasenleithner SO; Speicher MR
Mol Cancer; 2022 Mar; 21(1):81. PubMed ID: 35307037
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
[TBL] [Abstract][Full Text] [Related]
19. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
20. Updates in Tumor Profiling in Gastrointestinal Cancers.
Perez K; Safran HP
R I Med J (2013); 2015 Oct; 98(10):21-4. PubMed ID: 26422541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]